Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 42 of 42 publications.

Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, Zhou J, Bennett L, Anthony M. A comparative real-world study evaluating the safety of gammagard liquid and other intravenous immunoglobulin therapies for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Poster presented at the 2023 AANEM Annual Meeting; November 2023. Phoenix, AZ.

Levesque L, Johannes CB, Lecciones JA, Giamberardino H, Marcelon L, Cohen C, Rojas A, Bennett L, Khromava A. Post-authorization safety study: cohort event monitoring for CYD-TDV dengue vaccine (DNG15). Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):592. doi: 10.1002/pds.5687

Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142

Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1

Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021 Sep 7;5(1):82. doi: 10.1186/s41687-021-00355-5

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-58. doi: 10.1016/S2468-1253(21)00110-2

Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057

Price MA, Joish VN, Schwartz S, Fish-Steagall A, Bennett L, Darden C, Tesfaye E, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: improvements in clinical outcomes, patients satisfaction, and weight with telotristat ethyl in the real-world. Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.

Darden C, Ray D, Goldstein G, Goss D, Garbinsky D, Bennett L, Price M, Thota R. Satisfaction survey of administration modes for Long-Acting (LA) Somatostatin Analog (SSA) therapy in patients with Neuroendocrine Tumors (NETS). Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.

Joish VN, Price MA, Schwartz S, Stanley S, Bennett L, Darden C, Tesfaye E, Mobley Q, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: a real-world evidence study evaluating patient-reported outcomes with Xermelo. Poster presented at the 2018 NANETS Annual Multidisciplinary NET Disease Symposium; October 4, 2018. Seattle, WA.

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DYC, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki RM, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA. Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin. 2013 Sep 4;29(11):1463-73.

Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 Mar 15;119(10):1908-15.

Burris HA, Beck JT, Rugo HS, Baselga J, Lebrun F, Taran T, Bennett L. Health-related quality of life in advanced breast cancer patients treated with everolimus and exemestane versus exemestane monotherapy. Poster presented at the ESMO 37th Congress; September 28, 2012. Vienna, Austria.

Zhou X, Sherrill B, Wu Y, Bennett L, Wang J. Evaluating effects of changing treatments in longitudinal studies. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 5, 2012. Barcelona.

Zafar SY, Grothey A, Bekaii-Saab T, Bendell J, Sherrill B, Bennett L, Mun Y, Sersch M, Dalal D, Hurwitz HI. Survival among metastatic colorectal cancer (MCRC) patients treated in a randomized controlled trial (RCT) vs an observational cohort study (OCS). Poster presented at the 37th Annual Congress of the European Society for Medical Oncology; September 1, 2012. [abstract] Ann Oncol. 2012 Sep 1; 23(Suppl. 9):191.

Burris H, Beck JT, Rugo H, Baselga J, Lebrun F, Taran T, Bennett L, Ricci J, Sahmoud T, Hortobagyi GN. Health-related quality of life (QoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane monotherapy. Poster presented at the ESMO 2012 Conference; September 2012. [abstract] Ann Oncol. 2012 Sep; 23(Suppl. 9):121-2.

Zafar Y, Grothey A, Bekaii-Saab TS, Bendell J, Sherrill EH, Bennett L. Survival among metastatic colorectal cancer patients treated in a randomized controlled trial versus an observational cohort study. Poster presented at the ESMO 37th Congress; September 2012. Vienna, Austria.

Beck JT, Rugo HS, Burris HA, Baselga J, Noguchi S, Gnant M, Pritchard KI, Bennett L. BOLERO-2: health-related quality of life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology; June 2012. Chicago, IL.

Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Wiezorek J, Douillard JY. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Nov 8; 29(15 Suppl):e19500. doi: 10.1038/bjc.2011.409.

Peeters M, Bennett L, Zhao ZY, Barber B, Zhou X, Zhang J, Xu F, Wiezorek J, Douillard JY. Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC). Poster presented at the European Society for Medical Oncology 13th World Congress on Gastrointestinal Cancers; June 2011. Barcelona, Spain. [abstract] Ann Oncol. 2011 Jun 1; 22(Suppl. 5):v24.

Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb 1;26(2):173-81.

Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.

Hollis KA, Tennis P, Nicandro J, Chuang E, Sweeney CT, Bennett L, Andrews E. Temporal trends in compliance with the alosetron risk management program. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.

Johannes C, Odom D, Bennett L, Foley D. The impact of menopause status on formal vs. informal care-seeking behavior in women with decreased sexual desire with associated distress. J Sex Med. 2010 May 1;7(Suppl. 3):123.

Nicandro J, Tennis P, Shin P, Hickman P, Bennett L, Hollis KA, Andrews E. One-year treatment continuation with alosetron is high irrespective of ibs-d severity criteria. Poster presented at the 2010 Digestive Disease Week; April 30, 2010.

Odom DM, Bennett L, Irish W, Mladsi DM. Statistical methods to handle incomplete longitudinal patient-reported outcomes data in advanced disease stage trials. Presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.

Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health. 2009 Apr 1;18(4):461-8.

Odom D, Devercelli G, Bennett L, Peeters M, Wolf M, Amado R. Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) versus bsc alone by kras tumor status. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 12, 2008. [abstract] Value Health. 2008 Nov; 11(6):487.

Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.

Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord. 2006 Feb 1;90(2-3):217-21.

Andrews EB, Hollis KA, Miller D, Tennis P, Bennett L, Ameen VZ, Heath A, McSorley D, Cook SF. A patient follow-up survey program for lotronex (Alosetron HCL): accessing compliance with the risk management program. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.

Gilsenan A, Pedrazzani S, Bennett L, Li L, Yeager W, Haas JC. Observational prevalence study of HSV-2 (Genital Herpes) in suburban primary-care practices: data collection procedures and sampling methods. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 21, 2003.

Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis. 2003 Apr 1;24(4):757-70.

Steenbergen C, Afshari CA, Petranka JG, Collins J, Martin K, Bennett L, Haugen A, Bushel P, Murphy E. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol. 2003 Jan 1;284(1):H268-76.

Amin RP, Hamadeh HK, Bushel PR, Bennett L, Afshari CA, Paules RS. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. Toxicology. 2002 Dec 27;181-182:555-63.

Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, Bennett L, Tennant R, Stoll R, Barrett JC, Blanchard K, Paules RS, Afshari CA. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci. 2002 Jun 1;67(2):219-31.

Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, DiAugustine RP, Barrett JC, Afshari CA, Dunn SE. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia. 2002 May 1;4(3):204-17.

Bushel PR, Hamadeh H, Bennett L, Sieber S, Martin K, Nuwaysir EF, Johnson K, Reynolds K, Paules RS, Afshari CA. MAPS: a microarray project system for gene expression experiment information and data validation. Bioinformatics. 2001 Jun 1;17(6):564-5.

Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol. 2001 Jan 1;8(6):625-37.

Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res. 2000 Jun 1;17(6):639-44.